Stent Wars
Boston Scientific must face trial in spat over stent patents
Johnson & Johnson logs win in Cordis-Medinol stent patent spat
J&J’s Conor MedSystems can’t slip $100M Biotronik lawsuit

Johnson & Johnson (NYSE:JNJ) subsidiary Conor MedSystems can’t slip a $100 million breach of contract lawsuit filed by former European distribution partner Biotronik, a New York state appeals court ruled last week.
Abbott claims win over Medinol in Dutch stent patent fight

ACC 2014 Roundup: Study shows long-term benefits for some CRT-D patients

Some patients with mild heart failure show significant, long-term benefits from cardiac-resynchronization therapy, according to the 7-year results from Boston Scientific‘s (NYSE:BSX) MADIT-CRT clinical trial presented at the American College of Cardiology’s annual meeting over the weekend.
Stent wars: Shrinkage concerns resurface in Medtronic/Boston Scientific DES trial

Supreme Court denies stent pioneer Saffran in $600M patent case against J&J’s Cordis

Johnson & Johnson‘s (NYSE:JNJ) Cordis stent-making arm won the final round in a patent infringement battle with stent pioneer Dr. Bruce Saffran when the U.S. Supreme Court yesterday declined to hear Saffran’s appeal.
Boston Scientific wins FDA approval for Promus Premier stent

Boston Scientific (NYSE:BSX) said the FDA granted pre-market approval for its next-generation coronary stent, the Promus Premier.
Natick, Mass.-based Boston Scientific said it plans an immediate release for the Promus Premier, a drug-eluting stent made of a platinum-chromium alloy coated with everolimus.
Federal Circuit denies re-hearing for Cordis patent claims against Medtronic, Abbott, Boston Scientific

A federal appeals court last week declined to revisit its decision to uphold the invalidation of patents covering drug-eluting stent technology.
Boston Scientific settles stent patent spat with OrbusNeich

Boston Scientific (NYSE:BSX) agreed to pay an undisclosed amount to put its long-running patent war with OrbusNeich Medical to rest.